Human GHRL(Ghrelin) ELISA Kit (E-EL-H1919)

This ELISA kit uses the Competitive-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with Human GHRL. During the reaction, Human GHRL in the sample or standard competes with a fixed amount of Human GHRL on the solid phase supporter for sites on the Biotinylated Detection Ab specific to Human GHRL. Excess conjugate and unbound sample or standard are washed away, and Avidin-Horseradish Peroxidase (HRP) conjugate are added to each micro plate well and incubated. Then a TMB substrate solution is added to each well. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns from blue to yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The concentration of Human GHRL in tested samples can be calculated by comparing the OD of the samples to the standard curve.

Somatostatin, also known as growth hormone-inhibiting hormone (GHIH), is a peptide hormone that inhibits the release of numerous hormones through G protein-coupled receptors. It is processed from a larger precursor into two bioactive forms, a 14-amino-acid and a 28-amino-acid peptide, is widely distributed in the central and peripheral nervous system, the gastrointestinal tract and the endocrine pancreas where delta cells are the main source, and is stored in secretory granules for stimulus-dependent release. Somatostatin acts through a family of five receptors, SSTR1 to SSTR5, that couple to Gi to inhibit adenylyl cyclase, reduce calcium influx and modulate potassium channels. In the anterior pituitary it suppresses growth hormone, thyroid-stimulating hormone and prolactin secretion, and in the gastrointestinal system it inhibits gut and pancreatic hormones including gastrin and cholecystokinin, slows gastric emptying, reduces intestinal motility, secretion and splanchnic blood flow, and inhibits insulin and glucagon release as an intraislet paracrine regulator. Because of these broad inhibitory actions, somatostatin serves as a brake on endocrine and exocrine secretion and on cell proliferation, and long-acting synthetic analogs such as octreotide and lanreotide are used to treat acromegaly and hormone-secreting neuroendocrine tumors. Measurement of somatostatin supports studies of neuroendocrine regulation, gastrointestinal physiology, control of growth hormone, insulin and glucagon secretion, and evaluation of neuroendocrine tumors.